Next Page
What is INQOVI?
There’s no
place like home
INQOVI tablets—the only oral hypomethylating agent (HMA) for the treatment of myelodysplastic syndromes (MDS) and CMML.
Appropriate patients can take their therapy in the convenience and comfort of their own home or wherever they are.1
CMML=chronic myelomonocytic leukemia.
Who is INQOVI for?
INQOVI is indicated for treatment of adult patients with myelodysplastic syndromes (MDS), including1:
- previously treated and untreated, de novo and secondary MDS with the following French‑American‑British subtypes:
- refractory anemia
- refractory anemia with ringed sideroblasts
- refractory anemia with excess blasts
- chronic myelomonocytic leukemia
- intermediate-1, intermediate-2, and high-risk International Prognostic Scoring System groups
Decitabine and cedazuridine (INQOVI®) is the only FDA-approved oral HMA option in MDS (IPSS Intermediate-1 and above) that the National Comprehensive Cancer Network® (NCCN®) recommends could be a substitution for IV decitabine1,2
Oral decitabine and cedazuridine (DEC-C) (NCCN Category 2A*) could be a substitution for intravenous decitabine in patients with IPSS intermediate-1 and above in the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Myelodysplastic Syndromes.2
- Do not substitute decitabine and cedazuridine (INQOVI) for an IV decitabine product within a cycle.1
*Category 2A: Based upon lower-level evidence, there is uniform NCCN consensus that the intervention is appropriate.2
HMA=hypomethylating agent; IPSS=International Prognostic Scoring System; IV=intravenous; MDS=myelodysplastic syndromes; NCCN=National Comprehensive Cancer Network.